{
  "zip": "L4B 3B2",
  "sector": "",
  "longBusinessSummary": "StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. The company was formerly known as GeneNews Limited. StageZero Life Sciences Ltd. was founded in 1998 and is headquartered in Richmond Hill, Canada.",
  "city": "Richmond Hill",
  "phone": "905 209 2030",
  "state": "ON",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.stagezerolifesciences.com",
  "maxAge": 1,
  "address1": "70 East Beaver Creek Road",
  "industry": "",
  "address2": "Unit 30",
  "previousClose": 0.72467,
  "regularMarketOpen": 0.7518,
  "twoHundredDayAverage": 0.38501397,
  "trailingAnnualDividendYield": null,
  "payoutRatio": null,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.7518,
  "navPrice": null,
  "averageDailyVolume10Day": 31431,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.72467,
  "fiftyDayAverage": 0.5468015,
  "trailingAnnualDividendRate": null,
  "open": 0.7518,
  "averageVolume10days": 31431,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 4.8099,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.71,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 4188,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 35959176,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 8343,
  "priceToSalesTrailing12Months": 22.349482,
  "dayLow": 0.71,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 4188,
  "fiftyTwoWeekHigh": 0.804,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.0256,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 0.7518,
  "exchange": "PNK",
  "shortName": "STAGEZERO LIFE SCIENCES LTD",
  "longName": "StageZero Life Sciences Ltd.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "GNWSF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_3103667",
  "uuid": "d118ec24-55f6-35c3-be35-7df51a81b50f",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": 23.612,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": -11.944,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 48940100,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": -0.165,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.0027,
  "netIncomeToCommon": -7933238,
  "trailingEps": -0.201,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.051009998,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 47937137,
  "enterpriseValue": 37990496,
  "threeYearAverageReturn": null,
  "lastSplitDate": 1600387200,
  "lastSplitFactor": "1:8",
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.7518,
  "logo_url": "https://logo.clearbit.com/stagezerolifesciences.com"
}